- Home
- CANF vs SMTI Comparison
CANF vs SMTI Comparison
Compare CANF & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CANF | SMTI |
|---|---|---|
| Founded | 1994 | 1982 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 182.6M |
| IPO Year | 2011 | 2008 |
Fundamental Metrics
Financial Performance| Metric | CANF | SMTI |
|---|---|---|
| Price | $3.07 | $17.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $9,750.00 | $41.00 |
| AVG Volume (30 Days) | ★ 615.0K | 73.2K |
| Earning Date | 03-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,586,976.00 |
| Revenue This Year | $2,715,455.50 | $17.31 |
| Revenue Next Year | $101.06 | $12.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.47 |
| 52 Week Low | $0.17 | $16.05 |
| 52 Week High | $10.40 | $35.70 |
Technical Indicators
Market Signals| Indicator | CANF | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 37.25 | 40.06 |
| Support Level | $0.59 | $16.05 |
| Resistance Level | $4.74 | $21.14 |
| Average True Range (ATR) | 0.18 | 1.23 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 18.54 | 29.08 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.